Figure 2From: Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence and absence of foodMean plasma concentration in healthy volunteers vs. time profiles for Treatment A (OROS® hydromorphone 16 mg; fasting conditions) and Treatment C (OROS® hydromorphone 16 mg; fasting conditions and naltrexone block).Back to article page